Replies to post #149069 on Biotech Values

[biomaven0]

I actually think Merck seems to have a decent pipeline, but I can't say I follow the big pharma closely enough for my opinion to be worth much.

Bristol's PD-1 program is certainly pretty exciting in the oncology space.

Peter